Vaccines (Lysosomal Associated Membrane Protein)

Immunomic Therapeutics, Inc. (ITI) is at the forefront of biotechnology, focusing on the development of innovative vaccines through its proprietary UNiversal Intracellular Targeted Expression (UNITE®) platform. This platform is designed to harness the body's natural biochemistry to elicit broad immune responses, particularly in the field of oncology. The UNITE® technology enables the engineering of chimeric proteins that direct antigen-presenting cells to present specific antigens to the immune system via a targeted pathway. This mechanism is expected to drive robust immune responses, including the activation of both CD4+ and CD8+ T cells, which are crucial for effective antitumor activity.

The company has developed a diverse pipeline of investigational products leveraging the UNITE® platform, targeting various conditions such as glioblastoma, Merkel cell carcinoma, and triple-negative breast cancer. For instance, ITI-1000 utilizes dendritic cell therapy to generate a T cell-mediated immune response against malignant cells expressing the cytomegalovirus (CMV) protein, while ITI-3000 targets the large T antigen of Merkel cell polyomavirus. Additionally, ITI is exploring self-amplifying RNA vaccines and next-generation checkpoint inhibitors, showcasing the versatility of the UNITE® platform in addressing multiple therapeutic areas, including cancer, allergies, and infectious diseases.

United States

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the Universal Intracellular Targeted Expression (UNITE) nucleic acid immunotherapy platform. This investigational technology has the potential to alter how we use immunotherapy for a number of diseases, including cancer, allergy and infectious diseases.

Immunomic Therapeutics, Inc.

Company Details